Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients

Annika Dufour,Giuseppe Palermo,Evelyn Zellmeier,Gudrun Mellert,Guillemette Duchateau-Nguyen,Stephanie Schneider,Tobias Benthaus,Purvi M. Kakadia,Karsten Spiekermann,Wolfgang Hiddemann,Jan Braess,Sim Truong,Nancy Patten,Lin Wu,Sabine Lohmann,David Dornan,Debraj GuhaThakurta,Ru-Fang Yeh,Galina Salogub,Philippe Solal-Celigny,Anna Dmoszynska,Tadeusz Robak,Marco Montillo,John Catalano,Christian H. Geisler,Martin Weisser,Stefan K. Bohlander

Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients

2013

In chronic lymphocytic leukemia (CLL) patients, disruptions of the TP53 tumor suppressor pathway by 17p13 deletion (del17p), somatic TP53 mutations, or downregulation of microRNA-34a have been associated with a poor prognosis. So far, the impact of the various TP53 defects has not been evaluated in

Keywords:

Chronic lymphocytic leukemia
Immunology
Somatic cell
Disease
Downregulation and upregulation
Diabetes mellitus
Medicine
Suppressor
previously treated
disease progression
poor prognosis

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations